- Home
- AQB vs GOVX Comparison
AQB vs GOVX Comparison
Compare AQB & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AQB | GOVX |
|---|---|---|
| Founded | 1991 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 3.0M |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | AQB | GOVX |
|---|---|---|
| Price | $0.93 | $0.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 61.6K | ★ 250.2K |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.66 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,472,659.00 | ★ $2,489,145.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $400.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.77 | $0.12 |
| 52 Week High | $2.82 | $4.40 |
Technical Indicators
Market Signals| Indicator | AQB | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 34.90 | 26.02 |
| Support Level | $0.84 | $0.16 |
| Resistance Level | $1.05 | $0.86 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 13.51 | 5.19 |
Price Performance
Historical ComparisonAbout AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.